Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shuyansan Tablets is a traditional Chinese medicine (TCM) developed by the China Academy of Chinese Medical Sciences Institute of Chinese Materia Medica. It is specifically indicated for the treatment of acute pharyngitis characterized by lung-stomach excessive heat syndrome (肺胃实热证). The formulation is designed to clear heat, detoxify, and alleviate pharyngeal symptoms such as pain, swelling, and inflammation. It has been evaluated in a Phase II clinical trial (CTR20181394) in China, which was a randomized, double-blind, multi-dose, multicenter study assessing its efficacy and safety in patients with acute pharyngeal inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Shuyansan Tablets.